製品番号: HY-N2542

Tubeimoside III

(別名: ツベイモシドIII)

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD₅₀ of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.91%
CAS 番号: 115810-13-4
分子式: C₆₄H₁₀₀O₃₁
分子量:1365.46

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Tubeimoside III 構造式

CAS 番号: 115810-13-4

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (2)
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

IL-6

IL-1β

Interleukin Related アイソフォーム固有の製品をすべて表示 :

NO Synthase アイソフォーム固有の製品をすべて表示 :

体外実験

Tubeimoside III (4 μM; 0-15 h) inhibits NO production, reduces the expression levels of inflammatory factors, suppresses glycolysis and mitochondrial respiration, and increases pyruvate content in LPS (HY-D1056)-induced RAW264.7 cells. The mechanism involves the ATF3-IκBζ pathway and is independent of the NF-κB pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

RAW264.7 treated LPS (HY-D1056)
Concentration:

4 μM
Incubation Time:

Pretreated with 3 h, then co-incubation for 0, 6, and 12 h
Result:

Inhibited the mRNA levels of IL-1β, IL-6 and iNOS, but had no significant effect on the expression of TNF-α.

Western Blot Analysis^[1]

Cell Line:

RAW264.7 treated LPS (HY-D1056)
Concentration:

4 μM
Incubation Time:

Pretreated with 3 h, then co-incubation for 0, 1, and 4 h
Result:

Inhibited the level of IκBζ and increased the level of ATF3.

体内実験

Tubeimoside III (1 mg/kg; intraperitoneal injection; single dose) exhibits anti-inflammatory activity in a LPS (HY-D1056)-induced acute inflammation mouse model^[1].
Tubeimoside III (0.0075-0.11 μM; topical administration; single dose) shows anti-inflammatory activity by inhibiting ear edema in a TPA (HY-18739)-induced mouse ear edema model^[2].
Tubeimoside III (12 mg/kg; intramuscular injection; 1-3 days) possesses antitumor activity in mice inoculated with S₁₈₀ sarcoma cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6 mice aged 7-10 weeks old (20-25 g) treated LPS (HY-D1056)^[1]
Dosage:

1 mg/kg
Administration:

Intraperitoneal injection (i.p.); single dose: 3 hours before LPS modeling
Result:

Significantly attenuated splenic congestion, inhibited inflammatory cell infiltration in alveoli, prevented necrosis in liver lesions.
Reduced the mRNA and protein expression levels of inflammatory cytokines IL-6, IL-1β, and iNOS in lung and liver tissues.

Animal Model:

BALB/c mice treated S₁₈₀ sarcoma cells^[2]
Dosage:

12 mg/kg
Administration:

Intramuscular injection (i.m.); 1, 2 and 3 days
Result:

Reduced the tumor weight, with inhibition rates of 36.0%, 65.6% and 72.8% for 1 day, 2 days and 3 days administrations, respectively.

化学情報

CAS 番号 115810-13-4
性状 Solid
分子量 1365.46
分子式 C₆₄H₁₀₀O₃₁
Color White to off-white
SMILES

O[C@H]1[C@@]23[C@](CC(C)(C)CC3)([H])C4=CC[C@@]([C@@]5([C@H]([C@@](C)([C@@H](O[C@@]6([H])[C@]([C@H]([C@H](O)[C@@H](CO)O6)O)([H])O[C@]7([H])O[C@@](COC(C[C@](C)(O)CC(O[C@]8([H])[C@@H](O[C@@]9([H])[C@@H]([C@H]([C@H](O)CO9)O)O)[C@@H](O)[C@](O[C@H]8C)([H])O[C@@]%10([H])[C@](OC[C@H](O)[C@@H]%10O)([H])OC2=O)=O)=O)([H])[C@@H](O)[C@H](O)[C@H]7O)[C@@H](O)C5)CO)CC%11)C)([H])[C@]%11(C)[C@]4(C)C1
別名

ツベイモシドIII
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Cell

Molecular characterization of Ebola virus glycoprotein V75A substitution in the 2018-2020 epidemic. [Abstract]

2026 Feb 5;189(3):818-831.e19. PMID: 41576953
Res Sq

A pH-driven receptor switch from ACE2 to NPC1 enables endosomal entry of SARS-CoV-2. [Abstract]

2026 Mar 4:rs.3.rs-8437418. PMID: 41858825

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (73.24 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7324 mL

3.6618 mL

7.3235 mL

5 mM

0.1465 mL

0.7324 mL

1.4647 mL

10 mM

0.0732 mL

0.3662 mL

0.7324 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

濃度

体積

分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始)

体積 _(開始)

濃度 _(終了)

体積 _(終了)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (289 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Li WH, et al. Tubeimoside III inhibits lipopolysaccharide-induced inflammatory responses by reprogramming glycolytic metabolism. Authorea Preprints. 2024.

[2]. Yu TX, et al. Structure-activity relationship of tubeimosides in anti-inflammatory, antitumor, and antitumor-promoting effects. Acta Pharmacol Sin. 2001 May;22(5):463-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.7324 mL	3.6618 mL	7.3235 mL	18.3088 mL
	5 mM	0.1465 mL	0.7324 mL	1.4647 mL	3.6618 mL
	10 mM	0.0732 mL	0.3662 mL	0.7324 mL	1.8309 mL
	15 mM	0.0488 mL	0.2441 mL	0.4882 mL	1.2206 mL
	20 mM	0.0366 mL	0.1831 mL	0.3662 mL	0.9154 mL
	25 mM	0.0293 mL	0.1465 mL	0.2929 mL	0.7324 mL
	30 mM	0.0244 mL	0.1221 mL	0.2441 mL	0.6103 mL
	40 mM	0.0183 mL	0.0915 mL	0.1831 mL	0.4577 mL
	50 mM	0.0146 mL	0.0732 mL	0.1465 mL	0.3662 mL
	60 mM	0.0122 mL	0.0610 mL	0.1221 mL	0.3051 mL

Keywords

Tubeimoside III

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Tubeimoside III

Immunology/Inflammation Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Macrocyclic Compound Library

Glycoside Compound Library

Terpenoids Library

Glycolysis Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Angiogenesis-Related Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Heterocyclic Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 Tubeimoside III

Interleukin Related アイソフォーム固有の製品をすべて表示

NO Synthase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Tubeimoside III 関連分類

製品番号: HY-N2542